Bipolar Disorders Market to Break Above $6.1 Valuation


Westford, USA, Sept. 22, 2022 (GLOBE NEWSWIRE) — In recent years, there has been an increasing demand for treatment options for Bipolar Disorders Market. More than 41 million people suffer from bipolar disorder worldwide, according to the latest WHO report. This is partly due to growing public awareness of this disorder, as well as growing evidence that treatments such as cognitive-behavioral therapy (CBT) and medications can be very effective.

According to the National Alliance on Mental Illness, bipolar disorder is one of the most common mental disorders in the United States. In fact, in 2021, approximately 1.2 million Americans were living with bipolar disorder. The SkyQuest study suggests that approximately 4.4% of American adults have bipolar disorder.

One of the reasons for the growing demand for drugs in the global bipolar disorder market is that the disease can be very debilitating. Symptoms can include extreme mood swings, racing thoughts, and difficulty concentrating. In some cases, people with bipolar disorder also experience episodes of mania or hypomania. Fortunately, there are a variety of treatments available for people with bipolar disorder. These treatments can include medication, counseling, therapy, and lifestyle changes.

SkyQuest has released a new report on the bipolar disorder market. The report provides an in-depth analysis of key drivers and trends shaping the market.

Get a sample copy of this report:

Lithium holds a dominant position in the global polar disorder market

To help people living with bipolar disorder manage their symptoms and prevent these complications, there is a growing demand for medications for bipolar disorder. Medications available to treat bipolar disorder include mood stabilizers (like lithium), antipsychotics (like olanzapine), and antidepressants (like selective serotonin reuptake inhibitors, or SSRIs). While each drug on the bipolar disorder market has its own set of pros and cons, they all share a common goal: to help the person living with bipolar disorder lead a relatively stable and healthy life.

The number of people seeking treatment for bipolar disorder is increasing. This has led to an increased demand for psychiatric drugs that treat the disease. One of these drugs is lithium (Eskalith and Lithobid). Lithium is the most widely used medication for controlling the symptoms of bipolar disorder worldwide. It works by restoring balance in brain chemistry.

Another pharmaceutical drug in the global bipolar disorder market for the treatment of bipolar disorder is Risperidone. Risperidone is a medicine that can be used to control rage and irritability in people with bipolar disorder. It may also help reduce psychotic symptoms, such as delusions and hallucinations. Risperidone side effects may include weight gain, fatigue, jaw pain, and headache. Lithium and risperidone are considered safe when taken as prescribed by a doctor. However, people taking either medication should talk to their doctor about any potential interactions they may have with other medications they are taking.

Browse the report summary and full table of contents (ToC):

Over 275 clinical trials are active in the bipolar disorder market

As the psychiatric community continues to search for new and improved treatments for bipolar disorder, drug developers are working hard to develop drug options that will help people with this mental illness. According to a recent study published by SkyQuest, drug developers in the global bipolar disorder market intensified their R&D activities to develop drugs to treat bipolar disorder between 2015 and 2022. The study found that during this period, the number of clinical trials sponsored by corporate pharmaceutical companies increased by 57%. Our review suggests that most trials are in phase 2 and phase 4.

This indicates that companies in the bipolar disorder market are committed to finding better treatments for bipolar disorder and are spending more money on research. Increased funding may be one of the reasons we are seeing more progress in drug development for bipolar disorder. Another contributing factor may be the increasing number of people with this condition.

In 2007, there were only around 12 million people with bipolar disorder worldwide, but this number has increased to around 41 million in 2021. This suggests that companies in the bipolar disorder market are paying more attention to this problem and try to find better solutions. treatments. So far, most efforts to develop drugs for bipolar disorder have been unsuccessful. However, there is still hope that new drugs will be developed in the future.

Speak to the analyst for your custom needs:

CBD is gaining momentum for the treatment of bipolar disorders

Currently, there is a growing demand for CBD for the treatment of bipolar disorder. CBD has proven to be an effective treatment for this mental health issue. There are many reasons why the bipolar disorder market is experiencing increased growth, but one of the most important is that CBD does not interact with medications used to treat bipolar disorder.

CBD, or cannabidiol, is one of many cannabinoids found in cannabis. CBD has been shown to be effective in treating a number of different conditions, including bipolar disorder. CBD has been shown to be effective in treating symptoms of bipolar disorder such as mania, anxiety, and depression. CBD also has promising potential for treating other conditions such as chronic pain, PTSD, and more.

CBD in the bipolar disorder market has been shown to have a host of benefits, including reducing anxiety and inflammation, calming the mind, and reducing manic symptoms. Plus, it’s non-addictive, which means people don’t experience the psychoactive effects of marijuana when consuming CBD.

Therefore, it is likely that CBD will continue to be increasingly used as a treatment option for bipolar disorder. Additionally, CBD may also prove useful in other mental health conditions, such as schizophrenia and major depressive disorder.

SkyQuest’s report provides an overview of the current bipolar disorder market landscape and offers insight into the potential opportunity for new therapies. The company believes its analysis will help policy makers better understand the market and make informed decisions about developing new treatments.

Bipolar Disorder Market Key Players

  • Allergan (Ireland)
  • AstraZeneca (UK)
  • Eli Lilly and Company (USA)
  • GlaxoSmithKline (UK)
  • Abbott (USA)
  • Bristol-Myers Squibb (USA)
  • Johnson & Johnson (USA)
  • Pfizer Inc. (USA)
  • Cephalon Inc. (USA)
  • Otsuka America Pharmaceutical Inc. (USA)
  • Gedeon Richter plc (Hungary)

Related Reports in the SkyQuest Library:

Global N-Acetylcysteine ​​Market

Global erectile dysfunction market

Global pancreatic cancer treatment market

Global Electroceutical Bioelectric Medicine Market

Global veterinary immunodiagnostics market

About Us:

SkyQuest Technology is a leading growth consulting firm providing market intelligence, marketing and technology services. It has more than 450 satisfied customers worldwide.


1 Apache Way, Westford, Massachusetts 01886


USA (+1) 617-230-0741

E-mail: [email protected]

LinkedIn Facebook Twitter


Comments are closed.